Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Med Insights Cardiol. 2010 Dec 1;4:117-28. doi: 10.4137/CMC.S4323.

Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease.

Author information

1
Departments of Family Medicine and Clinical Pharmacy, West Virginia University-Charleston Division, Charleston, West Virginia, USA.

Abstract

The thienopyridine antiplatelet agent clopidogrel is an effective drug for the prevention of vascular events. However, data has accumulated over time to suggest it is prone to significant interpatient variability. While there are several factors that contribute to this, one of the most important is variability in forming the active metabolite necessary for clopidogrel function. Several enzymes are involved in formation of this metabolite, and two, CYP2C19 and P-glycoprotein, appear to have alleles that both occur frequently in the population and have a clinically significant impact. Patients carrying these alleles can be identified, but it remains to be determined if this information is necessary or sufficient for risk stratification. Furthermore, if patients with high-risk alleles are identified, it is unclear how treatment should be adjusted.

KEYWORDS:

ABCB1; clopidogrel; cytochrome P4502C19; on-treatment platelet reactivity

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Libertas Academica Icon for PubMed Central
    Loading ...
    Support Center